Last reviewed 01/2018
This is a second generation centrally-acting antihypertensive which act as an agonist of the imidazoline I1 receptor in brainstem sympathetic nuclei.
Moxonidine is equally effective in reducing blood pressure as the current standard therapies (thiazides, beta-blockers and calcium antagonists). It is as effective as the first generation centrally-acting antihypertensives but has fewer side-effects.
Post-marketing surveillance reported a low incidence of adverse effects. Headache, dizziness, dry mouth and tiredness have been reported.
The summary of product characteristics should be consulted before prescribing this drug.